For the moment, this is a possible take away from a surprising loss the drugmaker suffered this week in a federal court, where a judge ruled that this sort of patent on its Baraclude treatment for hepatitis B is invalid.

FORBES: Not So Obvious: A Bristol-Myers Patent Defeat May Change Wall Street Views

In cases where doctors think a European visitor's treatment can wait until they get home, then the EHIC can be deemed invalid.

BBC: EU warns Spain over hospitals' rejection of EU health card